Pheochromocytoma and Diabetes

Pheochromocytoma is a rare catecholamine-secreting tumor of the adrenal medulla. About 30 to 50 percent of patients have hyperglycemia or diabetes because epinephrine and norepinephrine antagonize insulin. Diagnosis is biochemical first, then imaging; surgery — preceded by alpha-blockade — usually resolves both hypertension and glucose dysregulation.

What Pheochromocytoma Is

Pheochromocytomas arise from chromaffin cells of the adrenal medulla. Closely related tumors arising in extra-adrenal sympathetic and parasympathetic chains are called paragangliomas. Together they are uncommon — perhaps 2 to 8 cases per million per year — but clinically important because they are a curable cause of hypertension and diabetes.

• ~85 percent adrenal (pheochromocytoma) and ~15 percent extra-adrenal (paraganglioma)
• ~10 percent bilateral, ~10 percent malignant, ~30 to 40 percent hereditary
• The traditional “10 percent rule” understates the genetic component, which is closer to 30 to 40 percent
• Mean age at diagnosis is 30 to 50 years, with familial cases often younger

Why Pheochromocytoma Causes Diabetes

Catecholamines drive several effects that elevate blood glucose:

• Increased hepatic glycogenolysis and gluconeogenesis
• Inhibition of insulin secretion via alpha-2 adrenergic receptors on pancreatic beta cells
• Decreased peripheral glucose uptake
• Increased lipolysis and free fatty acid release contributing to insulin resistance

Hyperglycemia can be intermittent (matching catecholamine surges) or sustained. Severe cases occasionally present with diabetic ketoacidosis or hyperosmolar hyperglycemic state, but mild fasting hyperglycemia is more typical. For broader context on the spectrum of diabetes complications, see complications and related conditions.

Clinical Presentation

• Hypertension — sustained, episodic, or paroxysmal
• Episodes (“spells”) of headache, sweating, and palpitations
• Pallor (rather than flushing)
• Anxiety and a sense of impending doom
• Tremor
• Tachycardia and arrhythmias
• Orthostatic hypotension (volume depletion)
• Unexplained weight loss
• Constipation
• Hyperglycemia or new diabetes
• Cardiomyopathy (catecholamine-induced)
• Episodes triggered by exertion, anesthesia, foods rich in tyramine, certain medications

Triggers and Drugs to Avoid Before Diagnosis

How Clinicians Diagnose Pheochromocytoma

• Plasma free metanephrines (high sensitivity); patient supine, fasting, no recent stimulants
• 24-hour urine fractionated metanephrines and catecholamines (high specificity)
• Repeat testing or clonidine suppression for borderline results
• Adrenal CT with and without contrast, or MRI (better in pregnancy and for paragangliomas)
• Functional imaging — MIBG, 68Ga-DOTATATE PET/CT, or FDG-PET as indicated
• Genetic testing for hereditary syndromes — recommended for essentially all patients
• Co-secretion testing if features suggest other neuroendocrine activity (chromogranin A, calcitonin in MEN2)

Glucose Workup in Suspected Pheochromocytoma

• Fasting glucose and A1C — see A1C levels
• Ketone screening if symptoms suggest decompensation
• Lipid panel
• Electrolytes and renal function before contrast imaging

Differential Diagnosis

• Essential hypertension
• Panic disorder and anxiety
• Hyperthyroidism
• Carcinoid syndrome
• Drug effects (sympathomimetics, cocaine, amphetamines, SSRIs withdrawal)
• Renovascular hypertension
• Cushing syndrome
• Migraine
• Mastocytosis

Treatment

Treatment is multidisciplinary and follows a careful sequence:

• Preoperative alpha-blockade — phenoxybenzamine or selective alpha-1 blockers (doxazosin), titrated over 10 to 14 days
• Liberalized salt and fluid intake to expand intravascular volume
• Beta-blockade added later — only after alpha-blockade is established, for tachycardia or arrhythmias
• Other adjuncts — calcium-channel blockers, metyrosine in selected cases
• Adrenalectomy — laparoscopic when feasible; partial cortical-sparing approach in bilateral or hereditary disease
• Postoperative monitoring for hypotension and hypoglycemia (which is common immediately after tumor removal as catecholamine levels fall)
• Treatment of metastatic disease — surgical debulking, MIBG therapy, 177Lu-DOTATATE peptide receptor radionuclide therapy, chemotherapy (CVD regimen), tyrosine kinase inhibitors

Diabetes Management Before and After Surgery

• Before surgery, treat hyperglycemia conservatively because catecholamine-driven insulin resistance is partly reversible
• Avoid aggressive insulin titration that risks postoperative hypoglycemia
• After surgery, retest glucose and A1C and frequently down-titrate medications
• For residual diabetes, follow standard pathways — see treatment
• Address lifestyle, weight, and cardiovascular risk — see diet and nutrition

Genetic Syndromes

Prognosis

For benign, completely resected disease, long-term prognosis is favorable, but lifelong follow-up is recommended because of recurrence (about 5 to 15 percent) and the possibility of metachronous tumors, especially in hereditary disease. Malignant pheochromocytoma carries a more variable prognosis and warrants specialized multidisciplinary care.

When to See a Doctor

• Episodic headache, sweating, palpitations, and pallor
• Resistant hypertension or hypertension in a young patient
• New-onset diabetes with episodic symptoms
• Hypertensive response during anesthesia or surgery
• Family history of pheochromocytoma, paraganglioma, MEN2, VHL, or NF1
• Adrenal incidentaloma on imaging done for another reason

The Bottom Line

Pheochromocytoma is a rare but curable cause of hypertension and diabetes. Catecholamine excess drives glucose elevation in 30 to 50 percent of patients, and tumor removal usually reverses or substantially improves the metabolic disturbance. Because the genetic component is substantial, all patients should be offered genetic testing. Preoperative alpha-blockade before surgery is essential, and lifelong follow-up — biochemical and imaging — is standard. Talk to your doctor and consider endocrinology referral if your symptoms suggest pheochromocytoma.